Tool For Evaluating LASIK Outcomes Gets FDA Qualification
The US FDA has qualified a tool used to assess patient outcomes of LASIK surgery as scientifically valid. The qualification aims to support the agency’s pre- and post-market regulatory decisions and aid manufacturers in the development of devices for the procedure.
You may also be interested in...
A group of patient advocates including one former US FDA official met with agency staff on Sept. 13 to raise awareness about adverse events tied to LASIK surgery. The group said the vision-correcting procedure is too risky to be offered as elective surgery.
Fees for filing a premarket application with the US FDA increased 2.5% for fiscal year 2022, which is significantly less than the 7% they went up last year.
Research from the University of California, San Francisco claims that many deaths involving medical devices are incorrectly reported to the US agency, and says improving the accuracy of how these deaths are classified could improve patient safety.